Abstract. Curcumin and S-trans, trans-farnesylthiosalicylic acid (FTS) are two promising anticancer agents. In this study, we demonstrated that the two agents exerted significant synergy in antitumor activity in various types of cancer cells with combination indices ranging from 0.46 to 0.98 (a value of less than unity indicates synergism). We have further shown that synergistic-targeted co-delivery of the two agents can be achieved via formulating curcumin in polyethylene glycol (PEG)-derivatized FTS-based nanomicellar system. Curcumin formulated in PEG-FTS micelles had small size of around 20 nm. The nanomicellar curcumin demonstrated enhanced cytotoxicity towards several cancer cell lines in vitro. Intravenous application of curcumin-loaded micelle (20 mg kg −1 curcumin) led to a significantly more effective inhibition of tumor growth in a syngeneic mouse breast cancer model (4T1.2) than curcumin formulated in Cremophor/EL (P<0.05).
INTRODUCTION
Curcumin, a hydrophobic polyphenol compound extracted from Curcuma longa, has a wide spectrum of pharmacological activities and holds promise in the management of various diseases, such as cancers, cardiovascular diseases, Alzheimer's disease, and diabetes (1) (2) (3) (4) (5) . Particularly, curcumin has drawn interests as a therapeutic and chemopreventive agent for cancers via suppressing multiple signaling pathways such as MAPKs, PI3K/AKT, and NF-κB and inhibiting tumor cell proliferation, invasion, metastasis, and angiogenesis with no obvious side effect (6) (7) (8) (9) (10) . Moreover, curcumin acts as a chemosensitizer that augments the cytotoxic effect of other chemotherapeutic drugs such as doxorubicin and cisplatin (11) (12) (13) .
S-trans, trans-farnesylthiosalicylic acid (FTS) is a synthetic farnesylcysteine mimetic that acts as a potent and especially nontoxic Ras antagonist (14, 15) . Constitutively active Ras caused by mutation in the Ras family of proto-oncogenes is present in one third of human cancers, with the highest incidence of mutational activation of Ras being detected in pancreatic and colon cancers (16, 17) . Ras is also activated in cancer cells by other mechanisms (18, 19) . FTS has been shown to cause significant reduction of Ras levels, showing antitumor activity in a wide range of human cancers without observable side effects (17, (20) (21) (22) . FTS also can work in combination with other anticancer drugs, such as valproic acid and PKF115-584 (23, 24) .
Both curcumin and FTS have issues of poor water solubility and limited oral bioavailability despite their potentials as anticancer agents (25, 26) . We have recently shown that PEGylation of FTS led to significantly increased solubility of FTS in aqueous solution (27) . A conjugate of one molecule of PEG5000 (PEG 5K ) with two molecules of FTS via a labile ester linkage (PEG 5K -FTS 2 (L)) well retained the FTS biological activity (27) . Interestingly, polyethylene glycol (PEG)-derivatized FTS self-assembled to form small-sized micelles that are effective in solubilizing other hydrophobic drugs such as paclitaxel (PTX) (27) . In addition, PEG-FTS-based micelles demonstrated synergistic antitumor activity with co-delivered PTX in vitro and in vivo (27) . In this study, we examined whether the combination of curcumin and FTS exerted a synergy in antitumor activity in various types of tumor cells. The potential of PEG-FTS-based micellar system in synergistictargeted delivery of curcumin was also investigated.
METHODS

Materials
Curcumin (synthetic) was purchased from TCI American (OR, USA). Dimethyl sulfoxide (DMSO), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), trypsin-EDTA solution, Triton X-100, and Dulbecco's Modified Eagle's Medium (DMEM) were all purchased from Sigma-Aldrich (MO, USA). FTS was synthesized and purified following the published literature (15) . Antibodies against p-Akt (S473) and Akt were purchased from Santa Cruz Biotechnology. HRPElectronic supplementary material The online version of this article (doi:10.1208/s12248-014-9595-6) contains supplementary material, which is available to authorized users. labeled goat antirabbit IgG was purchased from Amersham Biosciences (Piscataway, NJ, USA). Dulbecco's phosphatebuffered saline (DPBS) was purchased from Lonza (MD, USA). Fetal bovine serum (FBS) and penicillin−streptomycin solution were from Invitrogen (NY, USA).
Cell Culture
4T1.2 is a mouse breast cancer cell line, and Panc02-H7 (H7) is a mouse metastatic pancreatic cancer cell line. DU145 and PC3 are two human androgen-independent prostate cancer cell lines. A549 is a human lung cancer cell line, and MCF7 is a human breast cancer cell line. All these cell lines were cultured in DMEM medium containing 10% FBS and 1% penicillin-streptomycin at 37°C in a humidified environment with 5% CO 2 .
Animals
Female BALB/c mice (4-6 weeks) were purchased from Charles River Laboratories. All animals were housed at controlled temperature and humidity according to AAALAC guidelines. All animal-related procedures were performed by fully following the protocol guidelines approved by the Animal Use and Care Administrative Advisory Committee of the University of Pittsburgh.
Synthesis of PEG 5K -FTS 2 Conjugate
PEG 5K -FTS 2 (L) is a conjugate of one molecule of PEG5000 (PEG 5K ) with two molecules of FTS via a labile ester linkage. PEG 5K -FTS 2 (S) is similar to PEG 5K -FTS 2 (L) in structure but has a relatively stable amide linkage between PEG and FTS (27) . PEG 5K -FTS 2 (L) and PEG 5K -FTS 2 (S) conjugates were synthesized and chemically characterized as described previously (27) . Briefly, for the synthesis of PEG 5K -FTS 2 (L), MeO-PEG 5k -OH (1 equiv.), succinic anhydride (5 equiv.), and 4-(dimethylamino) pyridine (DMAP, 5 equiv.) were mixed in DCM to yield carboxyl-terminated PEG monomethyl ether (MeO-PEG 5k -COOH). Diethanolamine (3 equiv.) was then coupled to the carboxylic group of MeO-PEG 5k -COOH (1 equiv.) using Nhydroxysuccinimide (NHS 3.6 equiv.) and dicyclohexylcarbodiimide (DCC 3.6 equiv.). PEG monomethyl ether with two hydroxyl groups (MeO-PEG 5k -(OH) 2 ) was purified by precipitation with ice-cold diethyl ether and ethanol respectively. PEG 5K -FTS 2 (L) conjugate was obtained by coupling MeO-PEG 5k -(OH) 2 (1 equiv.) to FTS (5 equiv.) via DCC (3 equiv.) and DMAP (0.3 equiv.) in chloroform. The mixed solution was filtered, and the final product was purified by precipitation in cold diethyl ether and ethanol respectively. PEG 5K -FTS 2 (S) was similarly synthesized except that MeO-PEG 5k -OH was first reacted with di-Boc lysine followed by deprotection of Boc using TFA. MeO-PEG 5k -(NH 2 ) 2 was then reacted with FTS via DCC and DMAP, and the final product was similarly purified as described above. The structures of PEG 5K -FTS 2 (L) and PEG 5K -FTS 2 (S) were confirmed by NMR ( Figure S1 ).
Preparation of Curcumin-Loaded Micelles
Curcumin (10 mM in chloroform) was mixed with PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) (10 mM in chloroform) at various carrier/drug molar ratios. The chloroform was removed by a stream of nitrogen to generate a thin film at the bottom of the glass tube, and the residual organic solvent was further removed under vacuum for 2 h. Subsequently, the thin film was hydrated and suspended in DPBS to form the curcumin-loaded micelles. The unincorporated curcumin was removed by filtration through a syringe filter (pore size, 0.22 μm). The drug-free micelles were similarly prepared as described above.
Characterization of Curcumin-Loaded Micelles
The average size and polydispersity index (PDI) of blank and curcumin-loaded micelles were measured by Zetasizer (Zetasizer Nano ZS instrument, Malvern, Worcestershire, UK) under room temperature.
The morphology of micelles was examined through transmission electron microscopy (TEM). Briefly, curcumin micelles were diluted with DPBS and placed on a copper grid covered with Formvar. Samples were stained with 1% uranyl acetate, and imaging was performed at room temperature using TEM (JEM-1011, JEOL, Japan).
The drug-loading capacity (DLC) and drug-loading efficiency (DLE) of curcumin micelles were determined by reverse phase HPLC (Alliance, 2695-2998 system). Briefly, curcuminloaded micelles were prepared as described above and then filtered through a syringe filter (0.22 μm). Curcumin in the filtered and nonfiltered micelles was extracted with methanol and quantified by HPLC with a mobile phase consisting of methanol/0.3% acetic acid (80/20, v/v), a flow rate at 1 mL/min, and a UV detector. The DLC and DLE of curcumin micelles were calculated according to the following formula:
The colloidal stability of curcumin micelles with various carrier/ drug molar ratios was evaluated by following the changes in sizes of the particles at different times following sample preparation.
Cytotoxicity Assay
Cytotoxicity assay was performed on 4T1.2, MCF7, A549, H7, DU145, and PC3 cell lines. All cells were plated at a density of 1,000 cells per well in 96-well plates and incubated for 24 h in DMEM with 2.5% FBS and 1% streptomycin/penicillin. Then, cells were treated with various concentrations of free FTS, free curcumin, and the combination of both respectively for 96 h. Viability of cells was evaluated by MTT assay as described (28) .
To test the cytotoxicity of curcumin-loaded PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) micelles, cells were treated with indicated concentrations of free curcumin, drug-free micelles, and curcuminloaded PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) micelles respectively for 96 h. MTT assay was then performed as described above.
Western Blot Analyses
Western blotting was performed to evaluate the protein expression levels of phospho-AKT in DU145 cells. Cells grown in six-wells plates with 80% confluency were treated with free PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) micelles, free curcumin, and curcumin-loaded micelles respectively for 12 h. Cells were washed twice with pre-cooled PBS and lysed in a buffer containing 0.2% Triton X-100 for 10 min on ice. Protein concentrations were determined, and equal amounts 50 1 is the concentration of FTS required to produce 50% effect alone, and d1 is the concentration of FTS required to produce the same 50% effect in combination with d2. D 50 2 is similarly the concentration of curcumin required to produce 50% effect alone, and d2 is the concentration of curcumin required to produce the same 50% effect in combination with d1. The CI values are interpreted as follows: <1.0, synergism; 1.0, additive; and >1.0, antagonism. Each experiment was done in triplicate of total protein lysate were resolved on a 15% SDS-PAGE and subsequently transferred to a nitrocellulose membrane. Membranes were blocked with 5% nonfat milk in PBS for 1 h prior to incubation with rabbit p-Akt or Akt primary antibody dissolved in PBST (DPBS with 0.1% Tween 20) overnight at 4°C. The blots were washed with PBST and then probed with goat antirabbit IgG for 1 h at room temperature followed by chemiluminescence detection. β-Actin was used as a loading control.
Transfection Assay
Transient transfections were performed on DU145 cells using the UF-2 transfection agent as described previously (29) . Briefly, the plasmid-UF2 complexes were formed by incubating 0.01 mg of NF-κB reporter gene and 0.04 mg of UF-2 transfection agent at room temperature for 20 min in a total volume of 400 μL of serum-free DMEM medium. The complexes were then mixed with freshly trypsinized cells in 5% FBS cell culture medium, and the cells were added to a 96-well plate at 50-70% confluency.
After 12 h of incubation, the transfection medium was replaced with medium that contained 10% fetal bovine serum laced with the designated concentrations of free FTS, free curcumin, free PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) micelles, and curcuminloaded PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S) micelles respectively. Cells were lysed with 0.2% Triton X-100 12 h later and assayed for luciferase activities. Transfection experiments were performed on at least three occasions, and in each case, experiments were done in triplicate. Data were represented as fold induction over reporter gene alone.
In Vivo Therapeutic Study
The syngeneic mouse tumor model 4T1 was generated by s.c. injection of 2×10 5 cells in 100 μL PBS into the right flank of each female BALB/c mouse. When the tumors reached~50 mm 3 in size, mice were randomized into four groups (N=5) for treatment. Mice were injected intravenously every other day for six times with 200 μL saline, blank PEG 5K -FTS 2 (L) micelles, curcumin in Cremophor EL (20 mg/kg), and curcumin-loaded )/2. To compare between groups, relative tumor volume (RTV=V/V 0 , V 0 was the tumor volume prior to the first injection) was calculated for each measurement. The mice were sacrificed when the tumors became larger than 1.5 cm in diameter or developed ulceration.
Statistical Analysis
In all statistical analyses, the significance was set at a probability of P<0.05. All results were reported as the means ±standard deviation. Statistical analysis was performed by Student's t test for two groups and one-way ANOVA for multiple groups, followed by Newman-Keuls test if P<0.05.
RESULTS
Effect of FTS and Curcumin on Cancer Cell Growth
The growth inhibitory activity of curcumin and FTS was assessed in a broad range of cancer cell lines including DU145 and PC3 (prostate), A549 (lung), H7 (pancreas), and 4T1 and MCF7 (breast). Curcumin or FTS caused a concentration-dependent inhibition of proliferation in all six cell lines (Fig. 1) , which was consistent with literature reports (3, 20, (30) (31) (32) . When we fixed the concentration of curcumin and gradually increased the concentration of FTS in co-treatment, the inhibition effect was progressively increased with increasing FTS concentration, indicating more effective tumor-killing effect in the combination treatment (Fig. 1) . Table I compares the cytotoxicity of single treatment and that of combination treatment at a representative FTS concentration of 25 μM in combination with curcumin. We calculated the combination index (CI) after co-administration of FTS and curcumin to assess whether the combination could confer synergistic, additive, or antagonistic effects (Table I) . CI was calculated by the equation CI = (d1/D 50 1)+(d2/D 50 2), with D 50 1 being the concentration of FTS producing 50% cell-killing effect in single treatment and d1 being the FTS concentration required to achieve the same 50% killing effect with d2 in co-treatment. Similarly, D 50 2 is the concentration of curcumin producing 50% killing effect in single treatment, and d2 is the curcumin concentration required to obtain the same 50% cell-killing effect in combination with d1. A CI of <1, =1, and >1 is suggestive of synergism, additive effect, and antagonism, respectively (33) . Data in Table I indicated that the combination of FTS and curcumin showed synergism in all of these examined cancer cell lines.
Characterizations of Curcumin-Loaded PEG 5K -FTS 2 Micelles
We have previously shown that a micellar system based on PEG 5K -FTS 2 (L) retained the biological activity of FTS and was capable of synergistic delivery of paclitaxel (27) . Following demonstration of synergy between curcumin and FTS in antitumor activity in various types of tumor cells, we then investigated whether curcumin can be formulated in PEG 5K -FTS 2 (L) micelles, leading to effective co-delivery of PEG-derivatized FTS and curcumin and the subsequent synergistic action between the two at the tumor site. Figure 2a shows that the particle size of PEG 5K -FTS 2 (L) was around 20 nm, which was consistent with our previous report (27) . Incorporation of curcumin into PEG 5K -FTS 2 (L) micelles had minimal impact on the average size and their size distribution (Fig. 2b) . TEM shows that both drug-free and curcumin-loaded PEG 5K -FTS 2 (L) micelles had spherical shape and were homogenous in size distribution (Fig. 2c, d) , which was consistent with the result of DLS analysis (Fig. 2a, b) . Table II shows the DLC and DLE at various carrier/drug molar ratios. Curcumin could be formulated in PEG 5K -FTS 2 (L) micelles at a carrier/drug molar ratio as low as 0.5:1. However, , and free curcumin respectively for 12 h. Western blotting was performed with total protein extracts using antibody against phospho-AKT. The same blot was reprobed with antibodies against total AKT as an internal control and β-Actin as a loading control the resulting mixed micelles were only stable for 2 h. Increasing the carrier/drug molar ratio was associated with an improvement in the colloidal stability of the curcumin-loaded micelles. Almost all of the input curcumin was loaded into the PEG 5K -FTS 2 micelles at a carrier/drug ratio of 2.5:1, and the resulting mixed micelles were stable for about 36 h. Curcumin/PEG 5K -FTS 2 mixed micelles prepared under this condition were used for all subsequent studies.
In Vitro Cytotoxicity of Curcumin/PEG 5K -FTS 2 Mixed Micelles
Curcumin was loaded into PEG 5K -FTS 2 (L) and PEG 5K -FTS 2 (S) micelles. Figure 3a shows the cytotoxicity of free curcumin and curcumin-formulated micelles in 4T1.2 cells. It was apparent that curcumin formulated in PEG 5K -FTS 2 (L) micelles was more active than free curcumin in inhibiting the proliferation of tumor cells. Similar results were observed in DU145 (Fig. 3b) and PC3 (Fig. 3c) cancer cells. Interestingly, curcumin formulated in PEG 5K -FTS 2 (S) micelles was comparable to free curcumin among the three cell lines tested (Fig. 3a-c) .
Effect of Curcumin/FTS Combination on AKT and NF-κB Pathways
To investigate the mechanism for the improved inhibitory effect of curcumin/ PEG 5K -FTS 2 (L) mixed micelles on cancer cells, we examined their effect on AKT and NF-κB pathways in DU145 cells as the two signaling pathways are critically involved in the rapid proliferation of various types of cancer cells (6, 7, 34, 35) , and both FTS and curcumin have been shown to negatively regulate the two pathways (6, 7, 35) . As shown in Fig. 4 , the level of pAKT was significantly downregulated following treatment with curcumin, which was consistent with previous reports (5,10,36) . The pAKT level was also decreased following treatment with either PEG 5K -FTS 2 (L) or PEG 5K -FTS 2 (S), although PEG 5K -FTS 2 (L) was more effective compared to PEG 5K -FTS 2 (S). It was also apparent that curcumin formulated in PEG 5K -FTS 2 (L) micelles was more effective in inhibiting the phosphorylation of AKT compared to the treatment of either alone (Fig. 4) . Figure 5 shows the effect of FTS and curcumin on NF-κB signaling as examined in a NF-κB reporter assay. NF-κB activity was significantly inhibited by treatment with either curcumin or FTS alone. However, the inhibition of NF-κB activity was further enhanced by the combination treatment. It is also apparent that curcumin formulated in PEG 5K -FTS 2 (L) micelles was more effective in inhibiting NF-κB signaling compared to PEG 5K -FTS 2 (L) micelles alone or curcumin formulated in PEG 5K -FTS 2 (S) micelles (Fig. 5) .
In Vivo Therapeutic Study
A highly metastatic 4T1.2 model (s.c.) was used to evaluate the in vivo antitumor activity of curcumin formulated in PEG 5K -FTS 2 (L) micelles. Curcumin formulated in Cremophor EL was used as a control. As shown in Fig. 6a , treatment with curcumin/Cremophor EL (six times, every other day) led to a modest inhibition of tumor growth at the early stage. However, there is a rebound in the growth rate of tumor following discontinuation of the treatment after d10. At d20, the tumors in curcumin/Cremophor EL-treated group became comparable to the tumors in PBS group in size. Curcumin formulated in PEG 5K -FTS 2 (L) micelles was significantly more effective than curcumin/Cremophor EL in inhibiting the tumor growth. The growth of the tumors remained significantly retarded following the discontinuation of the treatment after d10. Figure 6b shows the weights of the tumors collected at the end of the therapeutic study, which were consistent with the data of tumor growth curves (Fig. 6a) . All of the mice showed no signs of abnormal appearance, and no loss of body weight was found in these mice (Fig. 6c) .
DISCUSSION
In this study, we have demonstrated for the first time significant synergistic effect between curcumin and FTS in various types of cancers. We have also shown that curcumin can be effectively formulated in PEG-FTS micellar system, leading to enhanced antitumor activity in vitro and in vivo.
Various systems have been developed for delivery of curcumin including polymeric micelles, liposomes, and hydrogels (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) . Several polymeric micellar systems have been examined for delivery of curcumin including methoxy poly(-ethylene glycol)-zein, monomethyl poly(ethylene glycol)-poly(ε-caprolactone), methoxy-poly(ethylene glycol)-poly(-lactic acid)-tris-curcumin, methoxypoly(ethylene glycol)-bpoly(ε-caprolactone-co-p-dioxanone), poly(D,L-lac-tide-coglycolide)-b-poly(ethylene glycol)-b-poly(D,L-lactide-co-glycolide), and stearic acid-g-chitosan oligosaccharide micelle (41, 43, 44, (46) (47) (48) (49) . Incorporation of curcumin into polymeric micelles led to enhanced antitumor activity in a number of tumor models including lung, breast, and colon cancers (40) (41) (42) 48) . Curcumin-loaded micelles have also been shown to effectively inhibit tumor angiogenesis (40, 41) . However, most of the carrier materials in polymeric drug delivery systems do not have biological activity by themselves. PEG 5K -FTS 2 (L)-based micelles are derived from a promising anticancer agent and have been demonstrated to well retain FTS-mediated antitumor activity (27) . FTS-derivatized system shall be particularly suitable for delivery of curcumin as curcumin and FTS demonstrated significant synergy in various types of cancers (Fig. 1, Table I ). Indeed, curcumin formulated in PEG 5K -FTS 2 (L) micelles was more active than free curcumin in several cancer cells tested including 4T1.2, DU145, and PC3 (Fig. 3) . The improved cytotoxicity of curcumin formulated in PEG 5K -FTS 2 (L) micelles might be attributed to a synergistic action between the released curcumin and the free FTS that is cleaved from the PEG 5K -FTS 2 (L) conjugate following intracellular delivery of the mixed micelles. Another important mechanism might involve the protection of curcumin from decomposition by the PEG 5K -FTS 2 (L) micelles. Curcumin is known to undergo rapid degradation in a culture medium or buffer with physiological pH (50, 51) , and incorporation of curcumin into a delivery system has been shown to improve its bioavailability via slowing down the process of decomposition (43, 52) . Interestingly, curcumin formulated in PEG 5K -FTS 2 (S)-based micelles was comparable to or slightly less active than free curcumin in inhibiting the growth of cultured tumor cells (Fig. 3) . It might be due to the fact that PEG-FTS was largely designed for in vivo delivery and that in vitro cellular uptake of curcumin delivered via PEG-FTS micelles might be less efficient than that of free curcumin due to the steric hindrance imposed by PEG. This was supported by the data that the cytotoxicity of curcumin/PEG 5K -FTS 2 (L) mixed micelles is less active than the combination of free curcumin and FTS (Figs. 1 and 3) . It is possible that the PEG-FTS system can be further improved via incorporation of an active targeting ligand to facilitate intracellular delivery of curcumin/PEG-FTS mixed micelles.
The mechanism for the synergy between FTS and curcumin is not clearly understood at present. However, FTS and curcumin are known to inhibit both NF-κB and PI3K/AKT signaling pathways (6, 7, 32, 35, 36) . Our preliminary data clearly showed a synergy between curcumin and FTS in inhibiting either PI3K/AKT or NF-κB signaling, which likely contributes to the synergistic antitumor effect of the combination treatment.
The in vivo antitumor activity of curcumin/PEG 5K -FTS 2 (L) mixed micelles was examined in a syngeneic mouse tumor model, 4T1.2. 4T1.2 is an aggressive, metastatic breast cancer model. Although treatment with curcumin formulated in Cremophor/EL led to a modest inhibition of tumor growth at the early stage, there was a rapid rebound in the growth rate of the tumor. In contrast, tumor growth was inhibited by curcumin/PEG 5K -FTS 2 (L) mixed micelles in a more potent, sustained manner. A number of mechanisms are likely to be involved in the improved antitumor activity of curcumin formulated in PEG 5K -FTS 2 (L) micelles. First, PEG-FTS formed very small-sized mixed micelles with curcumin. Such small sizes (20~30 nm) shall ensure effective penetration into various types of solid tumors including poorly vascularized tumors (53, 54) . In addition, the potential synergistic antitumor activity between curcumin and the freed FTS will contribute to the overall improved antitumor activity. More studies are currently underway in our laboratory to further improve the PEG-FTS-based delivery system and to better understand the molecular mechanism for the improved antitumor activity of the nanomicellar curcumin.
